Journal article icon

Journal article

Non-alcoholic fatty liver disease concerns with glucokinase activators

Abstract:
We read with interest the Article in The Lancet Diabetes and Endocrinology by Dalong Zhu and colleagues, in which dorzagliatin, a dual-acting, allosteric glucokinase activator, showed a beneficial effect on glycaemic control in a phase 2 trial. Although the introduction of a new class of glucose-lowering drugs with a different mode of action is always welcome, particularly in this era of precision medicine, it is important to question the metabolic consequences of the dorzagliatin-induced reduction in plasma glucose.
Publication status:
Published
Peer review status:
Reviewed (Other)

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
RDM
Subgroup:
OCDEM
Brouwers, MCGJ More by this author
Publisher:
Elsevier Publisher's website
Journal:
Lancet Diabetes and Endocrinology Journal website
Volume:
6
Issue:
9
Pages:
684-685
Publication date:
2018-08-22
Acceptance date:
2018-06-06
DOI:
EISSN:
2213-8595
ISSN:
2213-8587
Pubs id:
pubs:911284
URN:
uri:8cf44540-3c85-412c-a376-34331c5f70e4
UUID:
uuid:8cf44540-3c85-412c-a376-34331c5f70e4
Local pid:
pubs:911284
Keywords:

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP